New 2-Aryloxy-3-phenyl-propanoic Acids As Peroxisome Proliferator-Activated Receptors α/γ Dual Agonists with Improved Potency and Reduced Adverse Effects on Skeletal Muscle Function
Citations Over TimeTop 24% of 2009 papers
Abstract
The preparation of a new series of 2-aryloxy-3-phenyl-propanoic acids, resulting from the introduction of a linker into the diphenyl system of the previously reported PPARalpha/gamma dual agonist 1, allowed the identification of new ligands with improved potency on PPARalpha and unchanged activity on PPARgamma. For the most interesting stereoisomers S-2 and S-4, X-ray studies in PPARgamma and docking experiments in PPARalpha provided a molecular explanation for their different behavior as full and partial agonists of PPARalpha and PPARgamma, respectively. Due to the adverse effects provoked by hypolipidemic drugs on skeletal muscle function, we also investigated the blocking activity of S-2 and S-4 on skeletal muscle membrane chloride channel conductance and found that these ligands have a pharmacological profile more beneficial compared to fibrates currently used in therapy.
Related Papers
- → Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat(1996)589 cited
- → Hepatic Peroxisome Proliferation: Induction by Two Novel Compounds Structurally Unrelated to Clofibrate(1975)346 cited
- → Structure-Activity Relationships for Hepatic Peroxisome Proliferation(1988)16 cited
- → Subcellular Organelle Biogenesis and Dynamics in Peroxisome Proliferation(1992)3 cited
- → Targeting peroxisome proliferator-activated receptors (ppar) for the treatment l-dopa-induced dyskinesias(2013)